According to Coherent Market Insights, the global achondroplasia market is estimated to be valued at US$ 93.82 million in 2022 and is expected to exhibit a CAGR
Brokerages predict that PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS – Get Rating) will report $5.83 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for PhaseBio Pharmaceuticals’ earnings, with estimates ranging from $2.50 million to $9.17 million. The business is scheduled to report its next earnings results on Monday, January […]